Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting
Details : Vitrakvi® (larotrectinib) is that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, which is investigated for the treatment of infantile fibrosarcoma.
Product Name : Vitrakvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer Receives Approval for Precision Oncology Treatment Vitrakvi™ in China
Details : Vitrakvi (Larotrectinib), is a first-in-class, highly selective TRK inhibitor exclusively designed to treat solid tumors that have an NTRK gene fusion, also called TRK fusion solid tumors. It has shown powerful efficacy with high and durable responses an...
Product Name : Vitrakvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In an expanded data set with a longer follow-up (cut-off July 15, 2019) of 175 patients (116 adult and 59 pediatric) with non-primary central nervous system (CNS) TRK fusion cancer, Vitrakvi demonstrated a durable, investigator-assessed overall response ...
Product Name : Vitrakvi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Larotrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable